5 Biomedical Stocks That Are Expected To Surge

Additionally, the company’s current Cash Flow growth sits at a whopping 201.66%, meaning that Anavex projects largely positive cash flows in the near future. Finally, Anavex has posted a strong 11.16 Current Ratio. Basically, the company is easily able to pay off its short-term debt obligations to its bondholders. Anavex Life Sciences Corporation holds a Zacks Rank #2 (Buy).

5. Enzo Biochem, Inc. (ENZ - Free Report)

Enzo Biochem develops, manufactures and markets healthcare products based on molecular biology and genetic engineering techniques. Enzo has beaten its earnings estimates in each of the past five operational quarters by an average of 51.33%. Additionally, Enzo received an “A” grade for Momentum, which means that shares could continue to grow on top of its 27.51% increase over the past twelve months. Also, Enzo Biochem’s projected EPS Growth stands at a whopping 65%, which towers over the industry average of 5.52%. And due to its solid earnings estimates, Enzo Biochem received a Zacks Rank #2 (Buy).

1 2 3
View single page >> |

Disclosure: Zacks.com contains statements and statistics that have been obtained from sources believed to be reliable but are not guaranteed as to accuracy or completeness. References to any ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Craig Newman 2 years ago Member's comment

Not any time soon! They have to wait for the Healthcare Bill to pass before traders spend another dime!